Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
October 21 2024 - 8:00AM
Business Wire
Brings 30+ years of commercial experience in
the orthopedic and spine industry
Bone Biologics Corporation (“Bone Biologics” or the
“Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic
products for spine fusion markets, announces the appointment of
Phillip T. Meikle to the Company’s board of directors, effective
immediately. Mr. Meikle succeeds Don R. Hankey, who retired from
the Board following seven years of service. The number of directors
of Bone Biologics remains at four.
Mr. Meikle most recently was president and chief executive
officer of Biosystems of New England, Inc., an orthopedic
distribution company that he founded in 1992 and sold to Stryker
Corporation in 2019. He has broad experience representing diverse
and innovative orthopedic and spine industry companies in
developing and distributing innovative products. Mr. Meikle has
been a consultant to Stryker Spine for the past five years.
Biosystems of New England served as a distributor for Stryker
Spine from 2002 to 2019, and for Medtronic Spine from 1992 to
2002.
“The appointment of Phillip Meikle to our board of directors is
particularly timely as we work to develop NB1 for spinal fusion
patients. He brings a wealth of experience with orthopedic and
spine products, and we look forward to benefitting from his
knowledge, experience and industry relationships. We are delighted
that a professional of Phil’s stature has agreed to join our
board,” said Jeffrey Frelick, president and chief executive officer
of Bone Biologics. “On behalf of Bone Biologics and our board of
directors, I extend heartfelt thanks to Don Hankey for his service
as Chairman and his long-standing support of our company, without
which we would not be where we are today.”
Mr. Meikle holds a B.S. from West Virginia University College of
Engineering. He has received numerous professional awards including
Inaugural Inductee in the Stryker Spine Hall of Fame and
Distributor of the year at both Stryker and Medtronic Danek
Spine.
About Bone Biologics
Bone Biologics was founded to pursue regenerative medicine for
bone. The Company is undertaking work with select strategic
partners that builds on the preclinical research of the NELL-1
protein. Bone Biologics is focusing development efforts for its
bone graft substitute product on bone regeneration in spinal fusion
procedures, while additionally having rights to trauma and
osteoporosis applications. For more information, please visit
www.bonebiologics.com.
Forward-Looking Statements
Certain statements contained in this press release, including,
without limitation, statements regarding the expected results and
performance of Mr. Meikle and the ability of the company to develop
the Company’s lead product candidate NB1 for spinal fusion
patients, as well as statements containing the words “look forward”
and words of similar import, constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve both
known and unknown risks and uncertainties. The Company’s actual
results may differ materially from those contained in its
forward-looking statements as a result of a number of factors,
including, but not limited to, market and other conditions and
risks generally associated with an undercapitalized developing
company, as well as the risks contained under “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” in the Company’s Annual Report on Form 10-K
for the year ended December 31, 2023 and the Company’s other
filings with the Securities and Exchange Commission. Except as
required by applicable law, the Company undertakes no obligation to
revise or update any forward-looking statements to reflect any
event or circumstance that may arise after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241021983057/en/
LHA Investor Relations Kim Sutton Golodetz 212-838-3777
kgolodetz@lhai.com
Bone Biologics (NASDAQ:BBLG)
Historical Stock Chart
From Oct 2024 to Nov 2024
Bone Biologics (NASDAQ:BBLG)
Historical Stock Chart
From Nov 2023 to Nov 2024